Infiltrative hepatocellular carcinoma, Hepatic arterial infusion chemotherapy, Lenvatinib, PD-1 inhibitor, Prognosis
Recurrent Hepatocellular Carcinoma, Intermediate-Stage, Transarterial Chemoembolization, Sorafenib, Radiofrequency Ablation
intrahepatic cholangiocarcinoma, Clonorchis sinensis, Tumor heterogeneity, Metabolism, fatty acid biosynthesis, FASN, immune microenvironment, TAM-like macrophages, prognosis, therapeutic target